ESK-440

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameESK-440
Drug Alias Namedual ALK/FAK inhibitor (Esanik Therapeutics/Michigan Center for Translational Pathology/Howard Hughes Medical Institute/University of Michigan Rogel Cancer Center)ESK-440
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsFocal adhesion kinase inhibitors
TargetsAnaplastic lymphoma kinaseFocal adhesion kinase
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesMichigan Center for Translational Pathology
China Registration ClassN/A

Develop Information

Active CompaniesHoward Hughes Medical InstituteMichigan Center for Translational PathologyUniversity Of Michigan Comprehensive Cancer Center +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A